We have invested heavily in a team of experts specializing in formulating the microsphere technology, and we currently have formulations with medical device applications in Advanced Wound Care, Surgical and Diagnostics as well as in the Drug Delivery segment.
Surgical and Diagnostics
In 2019 the company received CE approval for a technology product that is formulated for use in vascular occlusion in the treatment of tumors in liver and lung alongside cytostatic drugs. The product is manufactured at Magle Chemoswed and marketed by a distribution partner under the trade-name of EmboCept S. Alongside this we continue to increase our portfolio in the vascular occlusion area. We are actively working on our portfolio growth and building an occlusion franchise, through expansion in the product range. Alongside this we are supporting our distribution partner to enter the North American, Chinese and expanding European reach with the EmboCept range of products.
Advanced Wound Care
Our first advanced wound care product is currently in registration. A formulated hydrogel containing an antimicrobial for the treatment of chronic and diabetic wounds. The product is expected to received CE approval in 2020 and be distributed as a wound care hydrogel in Europe, Middle East and Russia through our existing agreement with our Russian and German partner.
First in Class Products
Based on our technology we have successfully patented a first in class product for the detection of pancreatic fluid leakage during surgical procedures. The product has been developed based on our technology and in partnership with the University Hospital of Heidelberg.